Clinical trials
Tumor Thrombus clinical trials
Below are recruiting tumor thrombus clinical trials, each written for real people, not researchers. We’re tracking 10 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07483359RecruitingPhase 2
Combination therapy for advanced liver cancer with portal vein tumor thrombus
This trial tests a combination of liver-directed chemotherapy, targeted therapy, and immunotherapy to shrink advanced liver cancer that has a blood clot in the portal vein (the main vein to the liver). The goal is to make the tumor removable by surgery.
Shenyang, LiaoningAges 18–80 - NCT05589207Recruiting
Model to predict outcomes in kidney cancer with IVC wall invasion
This study uses information from scans and surgery findings to build a prediction model for people with kidney cancer that has grown into a major vein (the IVC). It aims to help doctors better estimate outcomes and guide care after surgery.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05984511Recruiting
Combined treatment for liver cancer with portal vein tumor thrombus
This trial tests whether adding immunotherapy (atezolizumab/bevacizumab) and a type of internal radiation (I-125 seeds) to standard chemoembolization (TACE) can help people with liver cancer that has spread into the main liver blood vessel (portal vein). It aims to control the tumor and improve outcomes.
Guangzhou, GuangzhouAges 18–75 - NCT07799922Recruiting
Liver cancer treatment after immunotherapy
This trial tests a new procedure called IRE (a way to destroy tumors) for people with liver cancer that has not responded well to initial immunotherapy. It aims to help when surgery is not possible due to the tumor's size or location.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07776080RecruitingPhase 2
Immunotherapy, targeted therapy, and radiation for liver cancer with portal vein clot
This trial combines two immunotherapy drugs with a targeted therapy, radiation, and a liver-directed chemotherapy infusion for liver cancer that has spread to the portal vein (the main blood vessel to the liver). The goal is to see if this combination can shrink tumors and help people live longer.
Wuhan, HubeiAges 18–75 - NCT06622031Recruiting
TIPS with lenvatinib and immunotherapy for advanced liver cancer
This trial combines a procedure called TIPS (which helps relieve pressure in the liver) with two drugs—lenvatinib (a targeted therapy) and a PD-1 inhibitor (an immunotherapy)—for people with advanced liver cancer that has spread into the main vein of the liver. It aims to see if this combination can help control the cancer and improve symptoms.
Beijing, None SelectedAges 18–75 - NCT07117227Recruiting
Study to test a kidney cancer prediction model
This study is checking how well a model can predict the outcomes for people with kidney cancer who have had surgery. It looks at your medical records after surgery to help doctors better understand your recovery and future risks.
Beijing, Beijing MunicipalityAges 18–80 - NCT07062055RecruitingPhase 2
Combination therapy for advanced liver cancer that has spread
This trial tests a combination of liver-directed treatments and immunotherapy with a targeted drug for people whose liver cancer has spread to a few other organs. It aims to shrink tumors and improve outcomes.
Jinan, ShandongAges 18–70 - NCT05969496RecruitingPhase 2
Pembrolizumab plus axitinib before kidney surgery for RCC with IVC tumor
This Phase 2 trial tests whether pembrolizumab plus axitinib can shrink kidney cancer before surgery, when there is tumor growth into the inferior vena cava (IVC). It may help make the operation easier and improve chances of long-term control.
Aurora, ColoradoAges 18 years+ - NCT05319015RecruitingPhase 2
Combination drug therapy before surgery for kidney cancer with vena cava clot
This trial tests two drugs, lenvatinib and pembrolizumab, given before surgery to shrink kidney cancer that has spread into the large vein carrying blood to the heart (the vena cava). The goal is to see if this approach makes surgery more effective and improves outcomes.
Dallas, TexasAges 18 years+
Hear when a new Tumor Thrombus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for tumor thrombus?
- Yes. Clin2 currently lists 10 recruiting tumor thrombus studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a tumor thrombus trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a tumor thrombus trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.